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A data‑driven typology of asthma 
medication adherence using cluster 
analysis
Holly tibble1,2*, Amy Chan3,4, Edwin A. Mitchell5, Elsie Horne1,2, Dimitrios Doudesis1,6, 
Rob Horne2,4, Mehrdad A. Mizani1,2, Aziz Sheikh1,2,7 & Athanasios tsanas1,2
Asthma preventer medication non-adherence is strongly associated with poor asthma control. One-
dimensional measures of adherence may ignore clinically important patterns of medication-taking 
behavior. We sought to construct a data-driven multi-dimensional typology of medication non-
adherence in children with asthma. We analyzed data from an intervention study of electronic inhaler 
monitoring devices, comprising 211 patients yielding 35,161 person-days of data. Five adherence 
measures were extracted: the percentage of doses taken, the percentage of days on which zero 
doses were taken, the percentage of days on which both doses were taken, the number of treatment 
intermissions per 100 study days, and the duration of treatment intermissions per 100 study days. 
We applied principal component analysis on the measures and subsequently applied k-means to 
determine cluster membership. Decision trees identified the measure that could predict cluster 
assignment with the highest accuracy, increasing interpretability and increasing clinical utility. We 
demonstrate the use of adherence measures towards a three-group categorization of medication non-
adherence, which succinctly describes the diversity of patient medication taking patterns in asthma. 
The percentage of prescribed doses taken during the study contributed to the prediction of cluster 
assignment most accurately (84% in out-of-sample data).
Abbreviations
CART  Classification and regression tree
EMD  Electronic monitoring device
ICS  Inhaled corticosteroids
IQR  Interquartile range
PC  Principal component
PCA  Principal component analysis
RCT  Randomized controlled trial
US  United States
Asthma is a long-term condition that can be effectively managed in the majority of individuals through regular 
use of inhaled corticosteroids (ICS)1–3. Medication non-adherence, that is not taking a medication as prescribed, 
is however very common and is a major factor associated with poor asthma control, leading to increased likeli-
hood of asthma  attacks4–8. Sub-optimal adherence is a costly problem due to medication waste and unnecessary 
additional healthcare utilization to treat uncontrolled symptoms that may have arisen from non-adherence9–14.
Numerous studies have used targeted interventions to improve medication adherence in patients with asthma, 
with the aim of improving clinical outcomes (such as reducing the risk of asthma symptoms or attacks). While 
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some studies have shown positive changes in adherence behavior, they are usually short in duration, making 
their true clinical and cost-effectiveness hard to  assess15–25.
Electronic monitoring devices (EMDs) enable the real-time tracking of inhaler use, by means of a small 
electronic chip fitted onto an inhaler, which records the date and time of each dose taken. EMDs are commonly 
used in research studies aimed at measuring adherence to inhaler asthma  therapy26, as they can track the exact 
time and frequency of inhaler actuations. EMDs can thus measure medication use more accurately than either 
self-report or indirect adherence measurement methods such as using prescribing or dispensing records, which 
makes their data a valuable resource for investigating patterns of adherence behaviors.
There are many ways of measuring medication non-adherence and the correlation between these measures 
within the same data is heavily context  dependant27,28. There is currently no consensus on what should be con-
sidered the gold  standard27–30. Furthermore, despite the multitude of medication non-adherence  measures31, 
many intervention studies describe medication adherence using only a single average measure over time (such 
as reporting the percentage of days on which the prescribed doses of ICS were  taken32–36), without supporting 
rationale for their choice.
Previous studies of adherence using EMDs in asthma have most commonly used the proportion of prescribed 
doses that were  taken34,37–40, or the percentage of days on which adherence was deemed acceptable by the authors, 
according to timing of  doses38,41.
Adherence is often reported categorically by dichotomizing individuals into “good” and “poor” adherers, 
according to a binary threshold, commonly 80%40,42–50. This threshold, based on a hypothesised level of adherence 
required to maintain therapeutic effect, which may be considered arbitrary, as any such level would be condi-
tion and drug-specific51 and rely on consistency in the space between doses over  time52–54. Very few studies have 
attempted a more detailed and meaningful dissection, such as categorising based on trends over  time55,56, or by 
assessing multiple components of  adherence7,57,58.
This study aimed to investigate the underlying patterns of medication non-adherence in children with asthma, 
and to identify multidimensional behavior subgroups.
Methods
Data sources. We undertook a secondary analysis of data from a previously published randomized con-
trolled trial (RCT)37. Chan et al.37 investigated the effect of an EMD inhaler with an audio-visual reminder func-
tion (timed alarm) on ICS adherence. The study enrolled children who presented to the emergency department 
for acute asthma symptoms and were diagnosed with asthma by the emergency department medical team. The 
diagnosis process would usually include a clinical diagnosis based on the presentation and medical assessment, 
supported by pulmonary function tests.
There were 220 children enrolled, aged 6–15 years, of whom 110 were randomized to the control group, and 
110 to the intervention group. Both groups received the same EMD; however, in the intervention group, the 
EMD had the audio-visual function enabled, whilst the control group had this function disabled. The device was 
provided to study participants at the baseline appointment, and data from each device was collected at each of 
the three follow-up appointments (approximately week 8, week 16, and week 24).
The original study inclusion criteria were: children between 6 and 15 years, with physician-diagnosed asthma, 
presenting to the emergency department with an asthma attack, and on twice-daily ICS treatment (with or 
without additional asthma treatments). Diagnosis of a chronic lung disease other than asthma, or congenital 
heart disease, led to exclusion from participating in the study, as well as living outside of the Auckland, New 
Zealand catchment area.
Measures of adherence. In chronic disease management, it is common for patients to take intermissions 
of treatment (periods of consecutively missed doses), followed by re-initiations (returning to treatment following 
an intermission). As such, it is possible to categorise adherence measures into the subdomains of implementation 
(dose-taking within a  day31) and persistence (the incidence and duration of treatment intermissions lasting at 
least five days, as discussed by Andrade et al.59).
Twice daily asthma medications are typically taken in the morning and evening, to ensure consistent bio-
availability throughout a 24-h period. As such, we refer herein to a ‘dose’ as one or more actuations (puffs) of the 
inhaler during a 12-h period (midnight to midday, and midday to midnight). Each individual in this study, by 
virtue of the inclusion criteria, was on a twice daily regimen, and thus had two potential doses in a day (before 
and after midday). Herein we define five measures of adherence used in this analysis, calculated at the person-
level, with denominators excluding periods in which the electronic inhaler device was malfunctioning. Their 
algorithmic definitions are as follows:
The percentage of doses that were taken:
The percentage of days on which zero doses were taken:
The percentage of days on which both doses were taken:
(A)
Doses taken
2× Days with device
× 100
(B)
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The number of treatment intermissions, per 100 days of follow-up:
The duration of time spent on treatment intermissions, per 100 days of follow-up:
Data analysis. Using principal component analysis (PCA), we extracted the latent variables of the adher-
ence measures. Latent variables (also known as principal components) are linear functions of the original meas-
ures, which identify the underlying structure of the measures and avoid redundant  information60. We identified 
the minimum number of principal components required to explain at least 95% of the variance between the 
measures.
Principal components can be influenced by varying magnitudes of scale (e.g. range 0–1 versus range 0–1,000) 
in the input features. As a benchmark, we used only zero-centering (subtracting the mean from each value) to pre-
process the adherence measures prior to applying PCA. We also compared the computed principal components 
generated from the adherence measures when the measures underwent different pre-processing before applying 
PCA: (1) after scaling each variable to unit variance (subtracting the mean from each value, and dividing by the 
variance), and (2) using min–max scaling (each variable was scaled to lie between 0 and 1).
We used k-means clustering with 25 random initiations, searching through for the optimal number k of 
clusters (we searched for k = 1, 2, …, 15). We visually assessed the within groups sum of squares using a scree 
plot61, to determine the optimal number of clusters. For each method of scaling/centering applied to the data 
in the principal component computation, we performed clustering on bootstrapped samples of the principal 
components, repeating the process 1,000 times to assess the stability of the resulting clusters.
The optimal scaling method was selected as the one that led to the most stable clusters, formally assessed 
using measures derived from the Jaccard similarity coefficient.
The Jaccard coefficient of cluster solution  similarity62 is the mean Jaccard similarity between (1) the clusters 
constructed from the full sample, and (2) the corresponding cluster constructed from bootstrapped samples. The 
cluster in the bootstrap sample corresponding to the original cluster is determined as the one with the highest 
Jaccard similarity to the original cluster.
In this process, a bootstrap sample cluster is considered dissolved when the Jaccard similarity between the full 
data cluster and the associated cluster from a bootstrap sample is less than 0.563. As such, we can also measure 
the cluster dissolution rate, the proportion of bootstrap samples for which the cluster dissolved.
Finally, we trained standard classification and regression trees (CARTs)60, using each of the measures 
described above to estimate the adherence groups, using the computed cluster labels as ground truth. The trees 
were constructed using the Breiman et al.  algorithm64 with the following parameters:
• At least 20 patients must be at a node for a split to be considered,
• There must be at least 6 patients at any terminal node,
• The maximum tree height is 2 nodes,
tenfold cross-validation was conducted to estimate the optimal complexity parameter (threshold improvement in 
model fit required for a split to be retained) for use in the tree pruning in order to minimize the cross-validated 
error rate. The tree is then pruned according to this estimated complexity parameter.
The tree was built on 70% of the data (randomly sampled). A partition of 15% was used to generate a confu-
sion matrix for each measure; mapping the combinations of cluster labels and tree labels, to quantify the quality 
of the estimates produced by the decision tree. The best measure was selected by highest accuracy was identified, 
as follows:
We then used the remaining 15% of the data (the test set) to report the final accuracy.
All analyses were conducted in R version 3.5.1, and scripts for data cleaning, setup and analysis will be made 
available on GitHub, a platform which host open-source projects (https ://githu b.com/holly tibbl e/Elect ronic 
-Monit oring -Devic e-Adher ence-Typol ogy).
Ethics. Ethics approval was granted by the New Zealand Northern Y Regional Ethics Committee 
(NTY/08/12/116) and District Health Boards. Verbal and written informed consent was obtained at data col-
lection from the parent or guardian of all participants. Analysis and reporting in this study was performed in 
accordance with the relevant guidelines and regulations.
(C)
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Results
Data cleaning and missing data. A total of 220 children were enrolled into the study. There were nine 
participants (seven from the control group and two from the intervention group) who did not complete the 
study. Reasons for drop-out were loss to follow-up (n = 5), missing data from one or more follow-up appoint-
ment (n = 2), non-compliance with protocol (n = 1) and study withdrawal (n = 1). This left a total of 211 partici-
pants with data from all study follow-up periods for inclusion in this analysis, yielding 36,902 person-days of 
data.
There were 1,741 person-days of missing data, out of a total 36,902 person-days (5% missing). This was due 
to battery failure, indicated in the device log, rather than simply individuals missing doses. 55 (26%) children 
in the study sample had at least one day with missing data, with a median 22 days missing (interquartile range 
(IQR): 10–48, range 2–122) from a median 185 days of follow-up (IQR: 176–190, range: 155–210). These periods 
of missing data were removed, resulting in 35,161 person-days for analysis.
The peak hours for actuations were 7–10 AM (96% of actuations between midnight and midday) and 7–10 
AM (93% of actuations between midday and midnight).
Study population. The study population consisted of 108 boys and 103 girls, aged between 6 and 15 
(median 8) years. The most common ethnicity was White European origin (38%; eTable 1).
Adherence. In the control group, 36% of prescribed doses were taken, compared to 80% in the intervention 
group. 54% of the overall cohort (n = 114) had at least one treatment intermission (Fig. 1), with the first starting 
a median of 42 days after the baseline visit (IQR 14–95 days). Individual’s first treatment intermissions had a 
median duration of eight days (IQR 6–14 days).
The difference between the intervention arms was marked, with 27% (n = 29) of the intervention group par-
ticipants having at least one treatment intermission, compared to 83% (n = 85) in the control group.
Exploratory cluster analysis. The correlations between the adherence measures used herein have previ-
ously been  reported65. For each scaling method, the scree plot consistently found three as the most appropriate 
number of clusters. Computing the principal components from the unit-variance scaled measures gave the most 
robust solution (eTable 2). Table 1 shows the variable loadings for the first four principal components.
Determining clinically meaningful subgroups. Statistics to summarize the distribution of the meas-
ures by cluster are presented in eTable 3. Cluster 1 had the poorest adherence—taking on average (between 
individuals median) 16% of their prescribed doses and approximately 4.0 treatment intermissions of five or 
more days in length for every 100 days of follow-up. In Cluster 3, only 7 individual (11%) took any treatment 
Figure 1.  Histogram of the number of treatment intermissions (continuous abstinence of 5 days or longer) per 
person during study period.
Table 1.  Principal components to identify the latent variable structure of (unit-scaled) medication non-
adherence.
PC1 PC2 PC3 PC4
(A) Percentage of doses taken 0.98 − 0.18 − 0.03 0.02
(B) Percentage of days on which zero doses were taken − 0.99 − 0.04 0.10 − 0.09
(C) Percentage of days on which both doses were taken 0.93 − 0.36 0.04 − 0.05
(D) Number of treatment intermissions per 100 study days − 0.94 − 0.28 0.19 0.07
(E) Duration of treatment intermissions per 100 study days − 0.93 − 0.23 − 0.29 0.00
Percentage of variance explained 91% 6% < 1% < 1%
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intermissions, and on average they took 91% of their doses. For each measure, Cluster 2 was somewhere between 
the first and third clusters.
We constructed a decision tree for each adherence measure in isolation, using the cluster labels as the response 
variable, in a standard supervised learning set-up framework. We used a random 70% sample of the data as a 
training set and the remaining 30% as a testing set. The percentage of doses taken yielded the highest accuracy 
(i.e. the group using the decision tree matching the group computed using the exploratory clustering approach) 
at 88%. The resulting decision tree (Fig. 2) had an accuracy of 84% in the test set (Table 2). Figure 3A–E present 
the boxplots of the measures by group.






% days both doses taken 
Figure 2.  Decision tree for estimating exploratory adherence clusters.
Table 2.  Confusion matrix using the automatically determined cluster labels (used as ’ground truth’) and 






G1 4 2 0
G2 1 18 0
G3 0 0 5
Figure 3.  Boxplots of the five adherence measures by tree-derived groups. (A) Percentage of doses taken, 
(B) Percentage of days zero doses taken, (C) Percentage of days both doses taken, (D) Number of treatment 
intermissions per 100 study days, (E) Duration of treatment intermissions per 100 study days.
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Discussion
In this study, we identified three exploratory clusters of adherence, which were found to be very stable across 
the 1,000 bootstrapped repetitions to assess cluster stability. These clusters, representing poor, moderate, and 
good medication adherence, were best approximated in a decision tree using the measure of the percentage of 
prescribed doses that were taken during the study (84% accuracy in data unseen to the training model).
Due to the limited follow-up time, we were required to aggregate adherence measures over the duration of the 
study. It is likely that with a larger sample and a longer follow-up we may have observed transitioning between 
states of behavior, perhaps triggered by clinical events such as an asthma attack. This study used data from 211 
children, and hence findings should be interpreted tentatively: it is possible that having more samples would 
enable finer stratification and exploration of additional clusters.
Some individuals with asthma are instructed to take their medication ‘as needed’, as they are able to maintain 
adequate asthma control despite taking medicine inconsistently. We did not remove such children from the 
population, as their adherence patterns remain of interest. We were additionally unable to stratify the popula-
tion accordingly due to the small sample size. In a larger study, it might have been that different groups were 
detected according to the strictness of their regimen, or that observed groups occurred in different frequencies.
The proportion of days on which both daily doses were taken was used as one of the measures of adherence. 
This measure was calculated assuming that one dose (of at least one actuation) was taken between midnight and 
midday, and one between midday and midnight. For the most part, this meant one dose in the morning, and 
one in the evening, as is usually recommended. However, if a dose was taken at 11.30 in the morning, followed 
by another at 12.30 in the afternoon, this would be recorded as having taken both the morning and evening 
doses, despite their being insufficient time between the doses for optimal distribution throughout the day. In this 
cohort, over 96% of morning and 93% of evening doses were taken within a 3-h window in each period (between 
7:00–10:00 o’clock in the morning window, and between 19:00–22:00 in the afternoon window). As such, this is 
unlikely to have been a common concern in the context of this study.
Finally, this study was undertaken in a narrow cohort with narrowly defined inclusion criteria i.e. children 
on a twice daily regimen for clinician-diagnosed asthma, with a recent history of emergency care presentation 
for an asthma attack. The generalizability of these findings to all children diagnosed with asthma, (or adults 
diagnosed with asthma) would therefore need to be further studied.
Future work. There is a need to study adherence patterns in adults with asthma, as well as in children (and 
adults) in primary care setting rather than only using a cohort of those with asthma related emergency depart-
ment presentations. As technology advances and the cost of manufacturing EMDs decreases, we envisage an 
increase in their adoption in clinical  care66,67, which may mean that future large scale studies can be conducted 
on routine practice datasets.
There are no studies which have attempted data driven categorisation, as far as we are aware. A recent study 
by Allemann et al. generated simulated pharmacy refill records according to six proposed adherence subtypes 
and attempted to detect them using data driven trajectory-based  models68. Trajectory-based models offer little 
scope for the integration of domain-specific knowledge. As the authors note, this means that identifying clusters 
which are clinically interpretable and meaningful according to their temporal patterns is challenging. While 
electronic monitoring devices are considered the gold standard for adherence measurement in asthma, adapt-
ing our methods to refill data may result in the identification of some of the clusters described by the authors. 
Furthermore, the application of such trajectory-based models in a (larger) electronic monitoring device dataset 
could potentially uncover some previously unidentified subgroups.
conclusions
Medication taking behavior in children with asthma is highly heterogeneous, and there is no consistent pattern 
of a patient with poor adherence. Through analysis of multiple adherence measures, we identified subgroups 
of asthma patients according to data-driven thresholds. Our findings suggest that the simple measurement of 
percentage of doses taken is sufficient in this population, and that combinations measures of non-adherence are 
unlikely to be of further clinical value than any of these measures in isolation.
Received: 11 October 2019; Accepted: 20 August 2020
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